trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'bcsm']
trastuzumab deruxtecan works better than chemo in patients with her2-low (previously known as her2-negative) as therapies get more powerful, we need better ways of measuring her2!
#asco22 #bcsm 
Geriatric Oncologist @incmnszmx #gerionc, Global Oncology. @ASCO BOD 20-24, FASCO. PhD @UNAM_MX Opinions my own. No FCOI. ???? https://t.co/GruVow1We8…